| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CLDNL; hCG1646163 |
| WB Predicted band size | 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CLDN23 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CLDN23抗体的模拟参考文献示例(请注意，CLDN23研究较为小众，以下内容为假设性示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**: "Development of a novel monoclonal antibody against CLDN23 for detecting intestinal barrier dysfunction"
**作者**: Tanaka K, et al.
**摘要**: 本研究开发了一种针对CLDN23蛋白的高特异性单克隆抗体，并通过免疫组化和Western blot验证其在人结肠组织中的表达。研究发现，CLDN23在炎症性肠病(IBD)患者的肠上皮细胞中表达显著下调，提示其可能作为肠道屏障完整性的生物标志物。
---
2. **文献名称**: "CLDN23 overexpression in gastric cancer and its interaction with HER2 signaling"
**作者**: Liu Y, et al.
**摘要**: 利用CLDN23多克隆抗体进行免疫组织化学分析，发现CLDN23在胃癌组织中的异常高表达与HER2信号通路激活相关。体外实验表明，抑制CLDN23可降低癌细胞侵袭能力，提示其作为潜在治疗靶点。
---
3. **文献名称**: "Structural characterization of CLDN23 in the blood-brain barrier using domain-specific antibodies"
**作者**: Müller S, et al.
**摘要**: 通过针对CLDN23胞外结构域的兔源多抗，研究揭示了CLDN23在血脑屏障内皮细胞中的定位及与紧密连接复合物的相互作用。研究为CLDN23在中枢神经系统疾病中的功能研究提供了工具支持。
---
如需实际文献，建议在PubMed或Google Scholar中检索关键词“CLDN23 antibody”或联系相关领域研究者获取最新进展。
The claudin-23 (CLDN23) antibody is a research tool targeting CLDN23. a member of the claudin family of transmembrane proteins critical for forming tight junctions in epithelial and endothelial cells. These junctions regulate paracellular permeability and maintain cellular polarity. CLDN23. though less studied compared to other claudins, is implicated in tissue-specific barrier functions and may play roles in pathological conditions. Its expression has been observed in organs like the intestines, kidneys, and liver, with emerging links to diseases such as inflammatory bowel disease (IBD) and certain cancers. For instance, altered CLDN23 expression has been associated with colorectal cancer progression, suggesting its potential as a biomarker or therapeutic target.
CLDN23 antibodies enable the detection and localization of the protein via techniques like immunohistochemistry, Western blotting, and immunofluorescence. These antibodies aid in studying CLDN23's interaction with other tight junction components, its regulation under physiological or pathological stimuli, and its involvement in pathogen entry or immune response modulation. Recent studies also explore its role in maintaining gut barrier integrity, where dysregulation could contribute to microbial translocation and inflammation. While most applications remain preclinical, CLDN23 antibodies hold promise for elucidating tissue-specific barrier mechanisms and developing targeted therapies. Further research is needed to clarify its precise functional roles and therapeutic relevance across diseases.
×
